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Previous molecular epidemiological studies on head and neck cancer have examined various 
single nucleotide polymorphisms (SNPs), but there are very few documented associations. In 
the International head and neck cancer epidemiology (INHANCE) consortium, we evaluated 
associations between SNPs in the metabolism, cell cycle, and DNA repair pathways and the 
risk of head and neck cancer. We analyzed individual-level pooled data from 14 European, North 
American, Central American, and Asia case–control studies (5,915 head and neck cancer cases 
and 10,644 controls) participating in the INHANCE consortium. Unconditional logistic regression 
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Europe (Canova et al., 2009), Heidelberg (Risch et al., 2003), Japan 
(Suzuki et al., 2007), Northeast US (Park et al., 2003), and India 
(Anantharaman et al., 2007). Descriptions of the individual studies 
are presented in the Table A1 in Appendix. To increase power, we 
included all controls selected for lung and kidney cancers in the 
Central Europe multicenter case–control study, in addition to the 
head and neck cancer controls. There were 6,694 head and neck 
cancer cases and 12,601 controls.
Cases and controls with missing data on age, sex, race/ethnicity, 
or SNP information, and cases with missing information on the 
site of origin of their cancer were excluded (779 cases and 1,957 
controls). In total, 5,915 cases and 10,644 controls were included 
in the analysis. Among the cases, 1,901 were oral cancer, 1,751 were 
pharyngeal cancer, 440 were cancers of the oral cavity or pharynx 
not otherwise specified, 1,632 were laryngeal cancer and 191 over-
lapping or subsite missing.
Written informed consent was obtained from all study subjects 
and the investigations were approved by institutional review boards 
at each of the institutes involved. Questionnaires were collected 
from all the individual studies, to assess the comparability of the 
collected data and of the wording of interview questions among the 
studies. Each data item was checked for illogical or missing values 
and inconsistencies were resolved as necessary.
Details on harmonizing questionnaire data have been published 
previously (Hashibe et al., 2007). Briefly, the definitions for ever 
smoking and drinking are different across studies. We reclassified 
ever tobacco smokers as those who have smoked at least 100 ciga-
rettes or 100 cigars or 100 pipes in their lifetime. In our previ-
ous analyses, drinking (≥3 alcoholic drinks/day) was associated 
increased HNC risks (Hashibe et al., 2007), we thus classified heavy 
drinkers as those who have consumed three or more alcoholic 
drinks per day.
Single nucleotide polymorphisms reported in more than two 
studies were included in the current pooled analyses. In total, 28 
SNPs in cell cycle (p21 Ser31Arg rs1801270 and p53 Pro72Arg 
rs1042522), DNA repair (ERCC2 Lys751Gln rs28365048, MGMT 
Leu84Phe rs12917, Ile143Val rs2308321, 171C > T rs1803965, 
OGG1 Ser326Cys rs1052133, XRCC1 Arg194Trp rs1799782, 
Arg280His rs25489, Arg399Gln rs25487, and XRCC3 Thr241Met 
rs861539), folate metabolism (MTHFR Ala222Val rs1801133 and 
Glu429Ala rs1801131), and carcinogen metabolism (ADH1B 
Arg48His rs1229984, ADH1C Ile350Val rs698, CYP1A1 Ile462Val 
rs1048943, 3801T > C E0322, CYP2E1 1054C > T rs2031920, 
was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for SNP effects, 
adjusting for age, sex, race, and country. We observed an association between head and neck 
cancer risk and MGMT Leu84Phe heterozygotes (OR = 0.79, 95% CI = 0.68–0.93), XRCC1 
Arg194Trp homozygotes Arg/Arg (OR = 2.3, 95% CI = 1.1–4.7), ADH1B Arg48His homozygotes 
Arg/Arg (OR = 2.7, 95% CI = 1.9–4.0), ADH1C Ile350Val homozygotes Ile/Ile (OR = 1.2, 95% 
CI = 1.1–1.4), and the GSTM1 null genotype (OR = 1.1, 95% CI = 1.0–1.2). Among these results, 
MGMT Leu84Phe, ADH1B Arg48His, ADH1C Ile350Arg, and the GSTM1 null genotype had 
fairly low false positive report probabilities (<20%). We observed associations between ADH1B 
Arg48His, ADH1C Ile350Arg, and GSTM1 null genotype and head and neck cancer risk. No 
functional study currently supports the observed association for MGMT Leu84Phe, and the 
association with XRCC1 Arg194Trp may be a chance finding.
Keywords: SNP, head and neck cancer, INHANCE
IntroductIon
Head and neck cancer, including cancers in oral cavity, pharynx 
(other than nasopharynx), and larynx, is the sixth most common 
cancer in the world (Parkin et al., 2005). It accounted for about 
900,000 of cases and 300,000 deaths in 2008 (Ferlay et al., 2010). The 
5-year survival rate was about 61% in the US for all sites (Altekruse 
et al., 2010) and 26 to 63% in Europe depending on the subsite 
(Berrino et al., 2007). The major risk factors for head and neck can-
cer are tobacco smoking and alcohol drinking (Hashibe et al., 2007). 
The interaction between tobacco smoking and alcohol drinking is 
greater than the expected multiplicative null with an overall attrib-
utable risk of 72% (Hashibe et al., 2009). Other risk factors include 
human papillomavirus (HPV) infection (IARC Working Group/
Human Papillomaviruses, 2007), passive smoking (Lee et al., 2008), 
low body mass index (BMI; Gaudet et al., 2010), poor diet (World 
Cancer Research Fund/American Institute for Cancer Research, 
2007), and family history of cancer (Negri et al., 2009).
Previous molecular epidemiological studies on head and neck 
cancer have examined single nucleotide polymorphisms (SNPs), 
focusing on metabolic and DNA repair genes (Sturgis and Wei, 
2002; Hashibe et al., 2003, 2008; Canova et al., 2009); however, 
very few SNP associations have been consistent for head and neck 
cancer risk. The heterogeneity may result from study design, e.g., 
population- or hospital-based controls, study sample size, and study 
populations, e.g., race/ethnicity (Hashibe et al., 2003; Lohmueller 
et al., 2003). The International head and neck cancer epidemiol-
ogy (INHANCE) consortium is a collaboration of research groups 
leading large molecular epidemiology studies of head and neck 
cancer. Since larger sample sizes can increase the precision of the 
effect measure estimates and the ability to detect statistically sig-
nificant moderate associations, we pooled data on SNPs that were 
genotyped in common across the INHANCE studies, to evaluate 
the associations between the SNPs in several pathways and the risk 
of head and neck cancer.
MaterIals and Methods
The INHANCE consortium (http://inhance.iarc.fr/) was estab-
lished in 2004. Fourteen studies participating in the consortium 
contributed SNP data: France (Benhamou et al., 2004), Central 
Europe (Hashibe et al., 2006), Seattle (Schwartz et al., 2001; Huang 
et al., 2005), Iowa (Wang et al., 2005), North Carolina (Olshan et al., 
2000), Los Angeles (Cui et al., 2006), Houston (Zhang et al., 2005), 
Puerto Rico (Hayes et al., 1999), Rome (Boccia et al., 2008), Western 
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1143A > T rs6413432, 1293G > C rs3813867, EPHX1 Try113His 
rs1051740, His139Arg rs2234922, GSTM1 null, GSTM3 Mnl 
AGG deletion rs1799735, GSTP1 Ile105Val rs947894, Ala114Val 
rs1799811, GSTT1 null, NQO1 Pro187Ser rs1800566) pathways 
were included. Hardy–Weinberg equilibrium was tested in the con-
trols by study. SNPs which did not pass the test in a specific study 
were excluded from the analyses.
The associations between SNPs and head and neck cancer 
risk were assessed by estimating odds ratios (OR) and 95% 
confidence intervals (CI) with unconditional logistic regres-
sion models for each study. The models included age (catego-
ries), sex, race/ethnicity (categories), and country (categories). 
In the Central Europe study, information on ethnicity was not 
collected and all subjects were classified as non-Hispanic white, 
since the majority of these populations were expected to be 
white. Pooled ORs were estimated with a fixed effects and ran-
dom effects (DerSimonian and Laird, 1986) logistic regression 
model. We assessed heterogeneity across studies by the likeli-
hood ratio test. Stratified analyses were conducted by cancer 
site (oral, pharynx, oral/pharynx not specified, and larynx), 
age (<45 and ≥45 years), sex, race (White, Black, Hispanic, and 
Asian) geographic region (Europe, North America, and Latin 
America), study type (hospital-based and population-based), 
study size (<300 cases and ≥300 cases), smoking (never and 
ever), drinking [≤3 and >3 drinks/day (Hashibe et al., 2007)] and 
fruit and vegetable intake (lower and higher than center-specific 
median among controls). The analyses were performed using 
SAS 9 and significant associations were defined as a two-sided 
p-value less than 0.05.
False positive report probability (FPRP; Wacholder et al., 2004) 
was assessed for all associations in which the two-sided null p-value 
was less than 0.05. FPRP was assessed for OR = 1.5 for probability 
of true association were 0.25, 0.1, 0.01, and 0.001. For the hap-
lotype analysis, we selected the studies that had information on 
the multiple SNPs for the gene. We used PHASE v2. (Stephens 
et al., 2001; Stephens and Donnelly, 2003) to reconstruct the hap-
lotype for genes with multiple SNPs available. Overall, haplotypes 
for four genes, CYP2E1, EPHX1, GSTP1, and MTHFR, could be 
reconstructed. The most frequent haplotype was treated as the 
referent group.
results
A total of 5,915 cases and 10,644 controls were pooled from 
14 studies in Europe (2,759 cases and 4,629 controls), North 
America (2,234 cases and 3,290 controls), Central America (147 
cases and 149 controls), and Asia (775 cases and 2,576 controls). 
Demographic characteristics of the cases and controls are pre-
sented in Table 1. Among the cell cycle and DNA repair SNPs, 
we observed associations between head and neck cancer risk and 
MGMT Leu84Phe heterozygotes (OR = 0.79, 95% CI = 0.68–
0.93) and XRCC1 Arg194Trp rare homozygotes (OR = 2.3, 95% 
CI = 1.1–4.7; Table 2).
For the carcinogen metabolism SNPs, associations were 
observed between head and neck cancer risk and ADH1B 
Arg48His His/His homozygotes (OR = 2.7, 95% CI = 1.9–4.0), 
ADH1C Ile350Val rare homozygotes (OR = 1.2, 95% CI = 1.1–
1.4), and the GSTM1 null type (OR = 1.1, 95% CI = 1.0–1.2; 
Table 1 | Demographic characteristics of head and neck cancer cases 
and controls.
 Cases Controls
  n % n %
All  5915  10644 
SEx
Female  1251 21.1 2765 26.0
Male  4664 78.9 7879 74.0
AgE
≤44  655 11.1 1545 14.5
45–49  628 10.6 1117 10.5
50–59  2014 34.0 3333 31.3
60–69  1664 28.1 2991 28.1
70+  954 16.1 1658 15.6
RACE
White  4676 79.1 7298 68.6
Black  267 4.5 383 3.6
Hispanic  117 2.0 273 2.6
Asian  811 13.7 2647 24.9
Others  44 0.7 43 0.4
STuDy COuNTRy    
France France 256 4.3 173 1.6
Central Europe Romania 103 1.7 185 1.7
 Poland 189 3.2 814 7.6
 Russia 303 5.1 805 7.6
 Slovakia 40 0.7 196 1.8
Seattle USA 360 6.1 560 5.3
Iowa USA 366 6.2 330 3.1
North Carolina USA 174 2.9 196 1.8
Los Angeles USA 320 5.4 915 8.6
Houston USA 828 14.0 865 8.1
Puerto Rico Puerto Rico 147 2.5 149 1.4
Rome Italy 277 4.7 293 2.8
Western Europe Czech Republic 111 1.9 152 1.4
 Germany 175 3.0 179 1.7
 Greece 190 3.2 160 1.5
 Italy 378 6.4 446 4.2
 Ireland 17 0.3 16 0.2
 Norway 110 1.9 137 1.3
 UK 236 4.0 301 2.8
 Spain 76 1.3 81 0.8
 Croatia 52 0.9 46 0.4
Heidelberg Germany 246 4.2 645 6.1
Japan Japan 320 5.4 1848 17.4
Northeast US USA 186 3.1 424 4.0
India India 455 7.7 728 6.8
Table 3). Further adjusting for cigarette smoking and alcohol 
consumption (Table A2 in Appendix) did not change the results 
greatly. In addition, XRCC1 Arg280His rare homozygotes showed 
an association with head and neck cancer risk after adjustment 
of cigarette smoking and alcohol consumption (OR = 3.3, 95% 
CI = 1.1–10).
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Table 4 shows the FPRP for the observed associations for the 
selected SNPS under a given range of probability of true associa-
tions. If the prior probability is greater than 10% and we assume 
the expected OR = 1.5, the FPRPs for MGMT Leu84Phe, ADH1B 
Arg48His, ADH1C Ile350Val, and GSTM1 were lower than 20%.
Odds ratios for selected SNPs by head and neck cancer subsite 
are shown in Table 5. ADH1B His48Arg and ADH1C Ile350Val were 
consistently associated with oral, pharyngeal, and oral/pharyngeal 
NOS cancer, but ADH1C Ile350Val was not associated with laryn-
geal cancer. The association of GSTM1 null genotype was observed 
only with oral cancer (OR = 1.2 95% CI = 1.0–1.3).
Figure 1 shows the stratified results for the selected SNPs, compar-
ing the rare homozygotes to the common homozygotes. The effects 
from ADH1B Arg48His tended to be stronger among ever smokers 
and heavy drinkers than non-smokers and light drinkers. The associa-
tions from ADH1C Ile350Val were much stronger among Hispanic and 
Asian; however, these were based on relatively small numbers (case/
control in the rare homozygotes: 16/10 for Hispanic and 2/3 for Asian).
Table 6 further evaluated the joint effects among smoking, drink-
ing, and the selected SNPs. There was no evidence for the interaction 
between drinking and ADH1B Arg48His and ADH1C Ile350Val, and 
smoking and GSTM1 on the risk of head and neck cancer.
Table 4 | False positive report probabilities (FPRP) for observed associations for selected SNPs.
SNPs  Ca Co OR
 FPRP for OR = 1.5 and for different 
     probabilities of a true association
     0.250 0.100 0.010 0.001
MGMT L84F Leu/Phe 307 823 0.79 0.014 0.041 0.319 0.825
 Phe/Phe 43 81 1.40 0.302 0.565 0.935 0.993
XRCC1 R194W Arg/Trp 155 359 1.02 0.719 0.885 0.988 0.999
 Trp/Trp 16 21 2.30 0.349 0.617 0.947 0.994
ADH1B R48H Arg/His 467 1194 1.15 0.387 0.655 0.954 0.995
 His/His 1710 3018 2.73 0.001 0.002 0.019 0.161
ADH1C I350V Ile/Val 1383 2252 1.06 0.463 0.721 0.966 0.997
 Val/Val 579 778 1.22 0.021 0.060 0.413 0.877
GSTM1 null 1906 3386 1.11 0.025 0.073 0.463 0.897
OR adjusted for age, sex, country, race.
Table 5 | Selected SNPs and the risk of head and neck cancer by subsite.
Oral  
OR (95% CI)
Pharynx  
OR (95% CI)
Oral/pharynx. NOS 
OR (95% CI)
Larynx  
OR (95% CI)
ADH1B His48Arg (ca/co) 541/5157 593/5157 208/5157 981/5408
His/His 1.00 1.00 1.00 1.00
His/Arg 1.46 (0.86–2.47) 0.98 (0.61–1.27) 1.06 (0.68–1.64) 0.87 (0.56–1.34)
Arg/Arg 2.37 (1.31–4.30) 5.71 (3.22–10.1) 2.27 (1.14–4.52) 1.50 (0.67–3.38)
Ptrend <0.01 <0.01 0.03 0.08
His/Arg or Arg/Arg 1.89 (1.29–2.78) 2.80 (2.00–3.92) 2.22 (1.34–3.69) 1.55 (1.16–2.07)
ADH1C I350V (ca/co) 980/6013 1097/6013 240/6013 940/5255
Ile/Ile 1.00 1.00 1.00 1.00
Ile/Val 1.18 (0.99–1.40) 1.10 (0.93–1.30) 1.16 (0.80–1.67) 0.90 (0.75–1.08)
Val/Val 1.40 (1.12–1.76) 1.22 (0.98–1.52) 2.08 (1.19–3.63) 1.11 (0.88–1.41)
Ptrend 0.01 <0.01 0.22 <0.01
Ile/Val or Val/Val 1.22 (1.04–1.44) 1.13 (0.97–1.32) 1.24 (0.87–1.76) 0.94 (0.80–1.12)
GSTM1 (ca/co) 1236/6637 1068/5911 260/5911 798/3620
Present 1.00 1.00 1.00 1.00
Null 1.15 (1.01–1.32) 0.95 (0.83–1.10) 1.06 (0.82–1.38) 1.06 (0.89–1.26)
OR adjusted for age, sex, country, and race.
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FIguRE 1 | Stratified analysis for selected SNPs: (A) ADH1B Arg48His; His/His vs. Arg/Arg (B) ADH1C Ile350Val: Val/Val vs. Ile/Ile; (C) gSTM1 null genotype.
No obvious associations were observed for the haplotypes of 
CYP2E1, EPHX1, GSTP1, and MTHFR (data not shown).
dIscussIon
Our results showed associations between head and neck cancer 
risk and genetic variants in MGMT Leu84Phe, XRCC1 Arg194Trp, 
ADH1B Arg48His, ADH1C Ile350Val, and the GSTM1. Among 
them, the results for XRCC1 Arg194Trp might be a false finding 
because the FPRP was high even if the prior probability was set to 
be high (0.25).
Among the four studies reported XRCC1 Arg194Trp, none of 
them were statistically significant with a total of 16 cases and 21 con-
trols in the Trp/Trp group (Table 4). In the International lung cancer 
consortium, which pooled five studies with 26 cases and 28 controls 
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be associated with MGMT hypermethylation (Ogino et al., 2007), 
which could cause mutations in other critical genes (Mukai and 
Sekiguchi, 2002). The observed association might be a result of the 
mutated gene or an unidentified causal SNP. More studies would 
be needed to explore the associations and the mechanisms between 
MGMT polymorphisms and head and neck cancer.
Both ADH1B and ADH1C gene belongs to the ADH class I family, 
which plays a major role in ethanol metabolism (Edenberg, 2000). 
ADH1C 350Val and 272Arg result in a faster metabolism of ethanol 
(Hoog et al., 1986; Carr et al., 1989). Earlier associations on ADH1B 
and head and neck cancer were based on Asian studies (Hori et al., 
1997; Yokoyama et al., 1999, 2001; Asakage et al., 2007; Hiraki et al., 
2007). Recently, two large case–control studies further confirmed the 
association in European populations (Hashibe et al., 2006, 2008). 
The current analysis included the above studies; however, none of 
the study is influential on the overall pooled estimates. The differ-
ences in the published results could be because the frequency of the 
His allele is extremely low in the European population (International 
HapMap Project, 2008). In our study, only 1.2% European sub-
jects carried the His/His genotype while 61.3% Asian participants 
had the polymorphism. Despite the differences in distribution, the 
effects from the SNP did not differ by populations (Figure 1). The 
effects from ADH1B Arg/Arg were stronger among ever smokers 
or heavy drinkers. People who carry the ADH1B Arg/Arg genotype 
also tended to consume more alcohol than those who carried the 
His/His or His/Arg genotype (Table A3 in Appendix).
Earlier studies found no association between ADH1C Ile350Val 
and head and neck cancers (Coutelle et al., 1997; Bouchardy et al., 
2000; Olshan et al., 2001; Sturgis et al., 2001; Wang et al., 2005) 
while some recent studies reported associations as main effects or 
combined effects with alcohol drinking (Harty et al., 1997; Peters 
et al., 2005; Hashibe et al., 2006). A large study (Hashibe et al., 
2008) combining data from Europe and Latin America further 
suggested associations of ADH1B, ADH1C, and ADH7 genes with 
head and neck cancer risk. In the present pooled analysis, which 
combined data from Europe, North America, Latin America, and 
Asia, we observed an overall 25% increased risk of head and neck 
cancer on ADH1C Ile350Val, especially among oral and pharyngeal 
cancer patients. The result from Asia was very unstable possibly 
due to the low frequency of the homozygotes in the population. 
Excluding the Asian study from the analysis did not change the 
results materially.
ADH1B Arg48His and ADH1C Ile350Val genes are only 
100 kb away and have strong linkage disequilibrium (LD > 0.65; 
International HapMap Project, 2008). However, after restriction 
to the ADH1B His/His or His/Arg  population, ADH1C Val/Val 
still showed strong association on head and neck cancer risk. The 
frequency was very low in the European population and thus the 
statistical power was low (data not shown).
GSTM1 belongs to the glutathione S-transferases (GST) fam-
ily producing phase II xenobiotic metabolic enzymes. The GSTs 
play a role in the metabolism of chemical carcinogens, especially 
with regard to those present in tobacco smoke (Peters et al., 2006). 
However, epidemiological studies on the associations between GSTs 
and head and neck cancer have been inconsistent. The inconsist-
ency could be attributed to study design, for example, population-
based controls vs. hospital-based controls, matching criteria, and 
in the rare homozygote group, reported a non-statistically significant 
association with increased lung cancer risk (Hung et al., 2008). In a 
meta-analysis on DNA damage response genes and head and neck 
cancer reported an increased oral cancer risk for XRCC1 194Trp in 
the Asian population; however, no association was observed in the 
Caucasian population (Flores-Obando et al., 2010). A meta-analysis 
investigated the associations between DNA repair gene polymor-
phisms and smoking and found that XRCC1 194Trp, 280His, and 
399Gln were associated with smoking behaviors (Hodgson et al., 
2010). Nevertheless, further adjusted for smoking and drinking 
behaviors did not change the results materially, even though the 
association with 280His becomes statistically significant (Table A2 
in Appendix). Further investigation into the XRCC1 function and 
its association in tobacco induced gene repair might be helpful to 
elucidate the associations with head and neck cancer risks.
Association between MGMT Leu84Phe and head and neck can-
cer risk was observed in the present report. The effects were similar 
regarding the cigarette smoking and alcohol drinking status, age, 
sex, and race (data not shown). The FPRP was 0.787 if the priority 
probability was very low (0.001). However, the associations between 
heterozygotes and rare homozygotes and head and neck cancer risk 
were in different directions. The results for the rare homozygotes 
were imprecise across the five studies provided the SNP (OR = 1.60, 
0.90, 0.80, 1.55, and 0.66). Excluding the largest study which pro-
vided 608 cases and 1925 controls (OR = 1.60) in the analyses 
yield an OR 0f 0.99 (0.33–3.02). Nevertheless, the function of the 
MGMT Leu84Phe rare allele is not thought to differ from that of 
common homozygotes (based on the purified protein in the repair 
of O6-methylguanine in vitro; Pegg et al., 2007). In addition, more 
than 500 SNPs have been identified in MGMT in Caucasians and 
∼60% of the identified SNPs have minor allele frequency greater 
than 0.05 (Bugni et al., 2007). The MGMT polymorphism might 
Table 6 | Joint effects of drinking and ADH1B Arg48His and ADH1C 
Ile350Val and smoking and gSTM1 on the risk of head and neck cancer.
Lifestyle SNP Case Control OR 95% CI
Drinking* ADH1B Arg48His    
 Light His/His or His/Arg 331 1773 1.00 
 Light Arg/Arg 949 2186 1.73 (0.96–3.14)
 Heavy His/His or His/Arg 292 503 1.96 (1.12–3.43)
 Heavy Arg/Arg 711 552 4.03 (0.95–17.0)
 Interaction   1.21 (0.43–3.41)
Drinking* ADH1C Ile350Val    
 Light Ile/Ile or Ile/Val 1458 4004 1.00 
 Light Val/Val 327 566 1.18 (0.88–1.59)
 Heavy Ile/Ile or Ile/Val 906 893 2.45 (1.79–3.37)
 Heavy Val/Val 197 117 2.42 (1.64–3.56)
 Interaction   0.97 (0.62–1.52)
Smoking GSTM1    
 No Present 398 1414 1.00 
 No Null 385 1246 1.16 (0.94–1.42)
 Yes Present 1328 1865 3.03 (1.78–5.17)
 Yes Null 1318 1761 3.11 (1.92–5.06)
 Interaction   0.86 (0.66–1.12)
*Heavy drinkers were defined as those who drank > 40 ml/day.
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cancer.gov/csr/1975_2007/, based on 
November 2009 SEER data submis-
sion, posted to the SEER web site, 2010
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In summary, we observed associations between ADH1B 
Arg48His, ADH1C Ile350Arg, GSTM1 null and head and neck 
cancer risk. An association for XRCC1 Arg194Trp was not well 
supported based on the FPRPs. Further investigation is needed 
for MGMT Leu84Phe for the mechanism. ADH1B Arg48His and 
ADH1C Ile350Arg could be risk factors or markers of other risk 
genes for head and neck cancer. Effect of GSTM1 is slightly associ-
ated with increased risk of head and neck cancer but inconsistent 
across subsites.
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 incident cases vs. prevalent cases (Geisler and Olshan, 2001). The 
GST enzymes are also known to be expressed differently by site 
(Pacifici et al., 1988; Moscow et al., 1989; Howie et al., 1990). In 
the present study, GSTM1 null genotype was associated with oral 
cavity cancer but not the other head and neck cancer sites.
Interestingly, race seems to be a potential effect modifier for the 
association between GSTM1 and head and neck cancer, with ORs 
of 1.1 for Whites, Blacks, and Hispanic and 1.3 for Asians, even 
though the CI overlapped. The OR for Asians in North America 
was 1.3 (case/control: 28/64, 95% CI = 0.11–16).
In addition, significant results were only observed in the hospi-
tal-based studies for the association between GSTM1 and head and 
neck cancer. Hospital-based studies in our study exclude individuals 
with previous or malignant disease, including respiratory disease 
(France, Rome, North Carolina, Northeast US, India), tobacco or 
alcohol related diseases (Central Europe and Western Europe) or 
from hospital visitors (Houston). The GSTM1 genotype distribu-
tion among the hospital-based controls may not reflect those of 
the base population in our study. Among controls, the hospital-
based studies had lower frequency of the null type GSTM1 than 
population-based studies (45 vs. 52%, p < 0.0001).
A limitation of our study is that the pooled analysis is based 
on a heterogeneous population from different geographic regions 
and ethnicities. However, heterogeneity across studies was not sig-
nificant for most of our results. In addition, stratified analysis was 
conducted to assess whether our observations were due to a specific 
geography and ethnicity. In addition, individual data was available 
and were harmonized according to standard protocol; thus, we were 
able to control the potential confounders consistently.
A genome-wide association study (GWAS) was performed inde-
pendently within the INHANCE consortium using HumanHap300 
platform (McKay et al., 2011). The GWAS used the Central Europe 
and Western Europe studies for the discovery phase and replicated 
the findings in another subset of the INHANCE consortium: Los 
Angeles, Houston, Latin America, IARC Multicenter, Boston, and 
Rome studies, in combination with additional studies not in the 
current pooled analyses. The ADH1C Ile350Val was strongly associ-
ated with the head and neck cancer in the discovery phase (p < 10−5) 
and was replicated in the replication phase. The ADH1B His48Arg 
was not tagged on HumanHap300 but was selected as a candidate 
gene for the replication and showed the strongest association in the 
replication phase (p = 3 × 10−12). Inconsistency has been observed 
between results from candidate gene approach and from GWAS 
in previous studies (Siontis et al., 2010). The consistent findings 
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analyses based on candidate gene approach further support the role 
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ogy. Our observations suggest that, while GWAS may lead to novel 
hypotheses by elucidating new disease associated loci, traditional 
hypotheses-driven associations should not be ignored.
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appendIx
Table A1 | Summary of individual studies involved in the current analysis.
 Case subjects Control subjects‡Study location 
(reference†)
Recruitment 
period
Platform/method¥
Source Participation 
rate, %
Age eligibility 
years
Source Participation 
rate, %
EuROPE
Paris, France (Benhamou 
et al., 2004)
1987–1992 PCR-RFLP Hospital 95§ NA Hospital 
(unhealthy)
95§
Central Europe (Banska 
Bystrica, Bucharest, 
Budapest, Lodz, Moscow)|| 
(Hashibe et al., 2006)
1998–2003 TaqMan Hospital 96 ≥15 Hospital 
(unhealthy)
97
Rome (Boccia et al., 2008) 2002–2007 PCR-RFLP Hospital 98 NA Hospital 
(unhealthy)
94
Western Europe (Canova 
et al., 2009)
2000–2005 APEX Hospital 82 Hospital 
(unhealthy)*
68
Heidelberg, Germany 
(Risch et al., 2003)
1998–2000 PCR-RFLP Hospital 96 <80 Population 
registry
62
NORTH AMERICA
Seattle, WA Crump et al. 
(2000), Huang et al. (2005), 
Schwartz et al. (2001)
1985–1995 PCR-RFLP, multiplex, or 
matrix-assisted laser 
desorption/ionization 
time-of-flight mass 
spectrometry
Cancer 
registry
54.4, 63.3¶ 18–65 Random digit 
dialing
63, 61¶
Iowa (Wang et al., 2005) 1993–2006 PCR-RFLP Hospital 87 >17 Hospital 
(healthy)
92
North Carolina (Olshan 
et al., 2000)
1994–1997 Multiplex Hospital 88 >17 Hospital 
(unhealthy)
86
Los Angeles, CA (Cui et al., 
2006)
1999–2004 PCR-RFLP Cancer 
registry
49 18–65 Neighborhood 67.5
Houston, TX (Zhang et al., 
2005)
2001–2006 PCR-RFLP Hospital 95 ≥18 Hospital 
visitors
>80
Northeast, US (Park et al., 
2003)
1994–2000 PCR-RFLP Hospital NA Hospital 
(unhealthy)
LATIN AMERICA
Puerto Rico (Hayes et al., 
1999)
1992–1995 PCR-RFLP or TaqMan Cancer 
registry
71 21–79 Residential 
records
83
ASIA
India (Anantharaman et al., 
2007)
2001–2004 PCR-RFLP Hospital NA Hospital 
(unhealthy)
Japan (Suzuki et al., 2007) 2001–2005 TaqMan Hospital 61 20–79 Hospital 
(unhealthy)
41
NA = not applicable/not available.
†Representative publication in which study methods are described.
‡All studies frequency matched control subjects to case subjects on age and sex. Additional frequency matching factors included study center (Central Europe), 
hospital (France study), ethnicity (Northeast US), neighborhood (Los Angeles study), and tobacco and alcohol habits (India).
§Participation rate was not formally assessed, estimated response rate reported.
|| Multicenter study.
¶Two response rates are reported because data were collected in two population-based case–control studies, the first from 1985 to 1989 among men and the second 
from 1990 to 1995 among men and women.
*The three UK centers (Glasgow, Manchester, and Newcastle) from the Western European study were chosen from the same family medical practice (population-
based).
¥The majority of the SNPs were genotyped by the methods.
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Table A3 | Mean and median of alcohol drinking (ml/day) by ADH1B 
Are48His genotype
Study Allele Mean Median p
Central Europe His/His or His/Arg 25.28 13.17 0.42
 Arg/Arg 25.01 11.36 
Western Europe His/His or His/Arg 21.12 9.47 0.01
 Arg/Arg 27.04 15.92 
Heidelberg His/His or His/Arg 45.96 27.69 
 Arg/Arg NA NA 
Japan His/His or His/Arg 23.58 7.92 <0.01
 Arg/Arg 28.71 23.76 
p-value was determined by Wilcoxon rank sum test.
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